ReviewBioscience reports2014
Ductal carcinoma in situ of the breast: morphological and molecular features implicated in progression.
Review in Bioscience reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 53 citations in OpenAlex.
- Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Correlation of sonographic features with prognostic factors in ductal carcinoma in situ of the breast: an exploratory study using ultrasound and shear wave elastography.BMC medical imaging · 2024Article
- The Role of eHsp90 in Extracellular Matrix Remodeling, Tumor Invasiveness, and Metastasis.Cancers · 2024Review
- Article
- T-type Ca2+ channels and their relationship with pre-neoplastic and neoplastic lesions in the human breast.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2023Article
- Is palpable DCIS more aggressive than screen-detected DCIS?Surgery open science · 2023Article
- Insights into the transition of ductal carcinomaCancer biology & medicine · 2022Article
- LncRNA IPW inhibits growth of ductal carcinoma in situ by downregulating ID2 through miR-29c.Breast cancer research : BCR · 2022Article
- Plasma Concentrations of Matrilysins MMP-7 and MMP-26 as Diagnostic Biomarkers in Breast Cancer.Journal of clinical medicine · 2021Article
- Potential biomarkers of ductal carcinoma in situ progression.BMC cancer · 2020Article
- Identification of aberrant gene expression during breast ductal carcinomaThe Journal of international medical research · 2020Article
- Beyond proteases: Basement membrane mechanics and cancer invasion.The Journal of cell biology · 2019Review
- Prognostic role of immune infiltrates in breast ductal carcinoma in situ.Breast cancer research and treatment · 2019Review
- Ductal carcinoma in situ: to treat or not to treat, that is the question.British journal of cancer · 2019Review
- A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk.Breast cancer research : BCR · 2019Article
- Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.Molecular carcinogenesis · 2019Article
- Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).British journal of cancer · 2018Article
- Breaking through to the Other Side: Microenvironment Contributions to DCIS Initiation and Progression.Journal of mammary gland biology and neoplasia · 2018Review
- Protective role of all-trans retinoic acid (ATRA) against hypoxia-induced malignant potential of non-invasive breast tumor derived cells.BMC cancer · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The spread of mammographic screening programmes around the world, including in developing countries, has substantially contributed to the diagnosis of small non-palpable lesions, which has increased the detection rate of DCIS (ductal carcinoma in situ). DCIS is heterogeneous in several ways, such as its clinical presentation, morphology and genomic profile. Excellent outcomes have been reported; however, many questions remain unanswered. For example, which patients groups are overtreated and could instead benefit from minimal intervention and which patient groups require a more traditional multidisciplinary approach. The development of a comprehensive integrated analysis that includes the radiological, morphological and genetic aspects of DCIS is necessary to answer these questions. This review focuses on discussing the significant findings about the morphological and molecular features of DCIS and its progression that have helped to uncover the biological and genetic heterogeneity of this disease. The knowledge gained in recent years might allow the development of tailored clinical management for women with DCIS in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.